These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

125 related articles for article (PubMed ID: 36463971)

  • 1. Effectiveness of pharmacogenomic tests including CYP2D6 and CYP2C19 genomic variants for guiding the treatment of depressive disorders: Systematic review and meta-analysis of randomised controlled trials.
    Arnone D; Omar O; Arora T; Östlundh L; Ramaraj R; Javaid S; Govender RD; Ali BR; Patrinos GP; Young AH; Stip E
    Neurosci Biobehav Rev; 2023 Jan; 144():104965. PubMed ID: 36463971
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Should a routine genotyping of CYP2D6 and CYP2C19 genetic polymorphisms be recommended to predict venlafaxine efficacy in depressed patients treated in psychiatric settings?
    Taranu A; Colle R; Gressier F; El Asmar K; Becquemont L; Corruble E; Verstuyft C
    Pharmacogenomics; 2017 May; 18(7):639-650. PubMed ID: 28480819
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combinatorial Pharmacogenomic Algorithm is Predictive of Citalopram and Escitalopram Metabolism in Patients with Major Depressive Disorder.
    Shelton RC; Parikh SV; Law RA; Rothschild AJ; Thase ME; Dunlop BW; DeBattista C; Conway CR; Forester BP; Macaluso M; Hain DT; Aguilar AL; Brown K; Lewis DJ; Jablonski MR; Greden JF
    Psychiatry Res; 2020 Aug; 290():113017. PubMed ID: 32485484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Protocol for a pharmacogenetic study of antidepressants: characterization of drug-metabolizing profiles of cytochromes CYP2D6 and CYP2C19 in a Sardinian population of patients with major depressive disorder.
    Pinna M; Manchia M; Pisanu C; Pinna F; Paribello P; Carta A; Meloni A; Conversano C; Del Zompo M; Mola F; Squassina A; Carpiniello B
    Psychiatr Genet; 2021 Oct; 31(5):186-193. PubMed ID: 34282075
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-Utility Analysis of Pharmacogenetic Testing Based on CYP2C19 or CYP2D6 in Major Depressive Disorder: Assessing the Drivers of Different Cost-Effectiveness Levels from an Italian Societal Perspective.
    Carta A; Del Zompo M; Meloni A; Mola F; Paribello P; Pinna F; Pinna M; Pisanu C; Manchia M; Squassina A; Carpiniello B; Conversano C
    Clin Drug Investig; 2022 Sep; 42(9):733-746. PubMed ID: 35930170
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Does obtaining CYP2D6 and CYP2C19 pharmacogenetic testing predict antidepressant response or adverse drug reactions?
    Solomon HV; Cates KW; Li KJ
    Psychiatry Res; 2019 Jan; 271():604-613. PubMed ID: 30554109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Multi-gene Pharmacogenomic Testing That Includes Decision-Support Tools to Guide Medication Selection for Major Depression: A Health Technology Assessment.
    Ontario Health (Quality)
    Ont Health Technol Assess Ser; 2021; 21(13):1-214. PubMed ID: 34484487
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Does Pharmacogenomic Testing Improve Clinical Outcomes for Major Depressive Disorder? A Systematic Review of Clinical Trials and Cost-Effectiveness Studies.
    Rosenblat JD; Lee Y; McIntyre RS
    J Clin Psychiatry; 2017 Jun; 78(6):720-729. PubMed ID: 28068459
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interethnic Variability in CYP2D6, CYP2C9, and CYP2C19 Genes and Predicted Drug Metabolism Phenotypes Among 6060 Ibero- and Native Americans: RIBEF-CEIBA Consortium Report on Population Pharmacogenomics.
    Naranjo MG; Rodrigues-Soares F; Peñas-Lledó EM; Tarazona-Santos E; Fariñas H; Rodeiro I; Terán E; Grazina M; Moya GE; López-López M; Sarmiento AP; Calzadilla LR; Ramírez-Roa R; Ortiz-López R; Estévez-Carrizo FE; Sosa-Macías M; Barrantes R; LLerena A;
    OMICS; 2018 Sep; 22(9):575-588. PubMed ID: 30183544
    [TBL] [Abstract][Full Text] [Related]  

  • 10. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
    Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
    J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Retrospective Review of Pharmacogenetic Testing at an Academic Children's Hospital.
    Roberts TA; Wagner JA; Sandritter T; Black BT; Gaedigk A; Stancil SL
    Clin Transl Sci; 2021 Jan; 14(1):412-421. PubMed ID: 33048453
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: A meta-analysis.
    Rosenblat JD; Lee Y; McIntyre RS
    J Affect Disord; 2018 Dec; 241():484-491. PubMed ID: 30149336
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rapid evidence review of the comparative effectiveness, harms, and cost-effectiveness of pharmacogenomics-guided antidepressant treatment versus usual care for major depressive disorder.
    Peterson K; Dieperink E; Anderson J; Boundy E; Ferguson L; Helfand M
    Psychopharmacology (Berl); 2017 Jun; 234(11):1649-1661. PubMed ID: 28456840
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical validity: Combinatorial pharmacogenomics predicts antidepressant responses and healthcare utilizations better than single gene phenotypes.
    Altar CA; Carhart JM; Allen JD; Hall-Flavin DK; Dechairo BM; Winner JG
    Pharmacogenomics J; 2015 Oct; 15(5):443-51. PubMed ID: 25686762
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials.
    Bousman CA; Arandjelovic K; Mancuso SG; Eyre HA; Dunlop BW
    Pharmacogenomics; 2019 Jan; 20(1):37-47. PubMed ID: 30520364
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Metabolizing status of CYP2C19 in response and side effects to medications for depression: Results from a naturalistic study.
    Calabrò M; Fabbri C; Kasper S; Zohar J; Souery D; Montgomery S; Albani D; Forloni G; Ferentinos P; Rujescu D; Mendlewicz J; De Ronchi D; Serretti A; Crisafulli C
    Eur Neuropsychopharmacol; 2022 Mar; 56():100-111. PubMed ID: 35152032
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association of CYP2C19 and CYP2D6 Poor and Intermediate Metabolizer Status With Antidepressant and Antipsychotic Exposure: A Systematic Review and Meta-analysis.
    Milosavljevic F; Bukvic N; Pavlovic Z; Miljevic C; Pešic V; Molden E; Ingelman-Sundberg M; Leucht S; Jukic MM
    JAMA Psychiatry; 2021 Mar; 78(3):270-280. PubMed ID: 33237321
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Use of antidepressants with pharmacogenetic prescribing guidelines in a 10-year depression cohort of adult primary care patients.
    Jessel CD; Mostafa S; Potiriadis M; Everall IP; Gunn JM; Bousman CA
    Pharmacogenet Genomics; 2020 Sep; 30(7):145-152. PubMed ID: 32433340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. CYP2C19 and CYP2D6 genotypes in Pacific peoples.
    Helsby NA
    Br J Clin Pharmacol; 2016 Nov; 82(5):1303-1307. PubMed ID: 27304207
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update.
    Hicks JK; Sangkuhl K; Swen JJ; Ellingrod VL; Müller DJ; Shimoda K; Bishop JR; Kharasch ED; Skaar TC; Gaedigk A; Dunnenberger HM; Klein TE; Caudle KE; Stingl JC
    Clin Pharmacol Ther; 2017 Jul; 102(1):37-44. PubMed ID: 27997040
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.